长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.02.006

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (2): 110-113.doi: 10.3969/j.issn.1004-616x.2022.02.006

• 论著 • 上一篇

长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义

梁峰, 张玮, 李飞, 王胜杰, 杜宇晶, 张迎春

河北北方学院附属第一医院普通外科, 河北张家口 075000

收稿日期:2021-12-01 修回日期:2022-02-18 发布日期:2022-04-07
通讯作者: 张迎春,E-mail:zhyingchun@sina.cn E-mail:zhyingchun@sina.cn
作者简介:梁峰,E-mail:lhq820203@126.com。
基金资助:
河北省卫计委医学科学重点课题计划(20210954);张家口市科技局指导性项目(2021104D)

Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis

LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun

Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei, China

Received:2021-12-01 Revised:2022-02-18 Published:2022-04-07

摘要/Abstract

摘要： 目的：探讨长链非编码RNA癌症易感性候选基因9(lncRNA CASC9)在结直肠癌组织中的表达及其临床意义。方法：收集结直肠癌患者癌组织和癌旁组织87例，采用实时荧光定量PCR (qPCR)法检测lncRNA CASC9的表达情况，分析lncRNA CASC9在结直肠癌组织和相应癌旁组织中的表达水平及其与临床病理指标的相关性，采用Kaplan-Meier法进行生存分析，Log-rank法检验lncRNA CASC9表达量与结直肠癌患者临床预后的关系。结果：lncRNA CASC9在结直肠癌组织较癌旁组织中表达明显升高(P<0.01)。结直肠癌组织中lncRNA CASC9的表达水平与癌组织的不同分化程度(χ²=6.877，P=0.032)、TNM分期(χ²=7.660，P=0.022)以及是否发生淋巴结转移(χ²=9.901，P=0.002)相关，而与性别、年龄、肿瘤直径、肿瘤位置均无明显相关关系(均为P>0.05)。Kaplan-Meier生存分析发现，lncRNA CASC9高表达患者总生存期和无进展生存时间均较lncRNA CASC9低表达患者明显缩短(χ²=17.91，P<0.01；χ²=11.23，P=0.001)。结论：lncRNA CASC9在结直肠癌组织中的表达明显升高，与结直肠癌的分化程度、TNM分期、淋巴结转移有关，其有可能成为判断结直肠癌患者预后的潜在生物标志物。

关键词: 结直肠癌, 长链非编码RNA, 癌症易感性候选基因9, 预后

Abstract: OBJECTIVE： To investigate expressions of long-chain noncoding RNA cancer susceptibility candidate 9 (lncRNA CASC9) in colorectal cancers and its relationships with clinical prognosis. METHODS： Eighty-seven cancer and adjacent tissues from patients with colorectal cancers were collected. Real time quantitative PCR was used to detect the expression levels of lncRNA CASC9 in the tissues. Relationships between the expression levels clinicopathological indicators were analyzed. Kaplan-meier survival analysis was performed，and log-rank method was used to test the relationship between the expression levels and clinical prognosis. RESULTS：The expression levels of lncRNA CASC9 in colorectal cancer were significantly higher than that in adjacent tissues (P<0.01) and were significantly correlated with different degrees of differentiation (χ²=6.877， P=0.032)， TNM stage (χ²=7.660， P=0.022) and lymph node metastasis (χ²=9.901， P=0.002)， but not with gender，age，tumor diameter and tumor locations (All P>0.05). Kaplan Meier survival analyses show that the overall survival and progression- free survival times among patients with high expression of lncRNA CASC9 were significantly shorter than those with low expression (χ²=17.91， P<0.01； χ²=11.23， P=0.001). CONCLUSION：lncRNA CASC9 was highly expressed in colorectal cancers and was related to the degree of differentiation，TNM stage and lymph node metastasis of the cancers. It may be useful as a diagnostic marker of colorectal cancers.

Key words: colorectal cancer, long chain noncoding RNA, cancer susceptibility candidate 9, prognosis

中图分类号:

R735.3

梁峰, 张玮, 李飞, 王胜杰, 杜宇晶, 张迎春. 长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(2): 110-113.

LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.

参考文献

[1] THANIKACHALAM K, KHAN G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164.
[2] DEKKER E, TANIS P J, VLEUGELS J L A, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
[3] ZHOU B, YANG H, YANG C, et al. Translation of noncoding RNAs and cancer[J]. Cancer Lett, 2021, 497: 89-99.
[4] NANDWANI A, RATHORE S, DATTA M. LncRNAs in cancer: regulatory and therapeutic implications[J]. Cancer Lett, 2021, 501: 162-171.
[5] IACCARINO I, KLAPPER W. LncRNA as cancer biomarkers [J]. Methods Mol Biol, 2021, 2348: 27-41.
[6] ZHANG Y L, LIU Q F, LIAO Q. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment[J]. J Exp Clin Cancer Res, 2020, 39(1): 231.
[7] CHEN S A, SHEN X. Long noncoding RNAs: functions and mechanisms in colon cancer[J]. Mol Cancer, 2020, 19(1): 167.
[8] QI Y Y, SONG C Y, ZHANG J L, et al. Oncogenic LncRNA CASC₉ in cancer progression[J]. Curr Pharm Des, 2021, 27(4): 575-582.
[9] BING Z X, HAN J S, ZHENG Z B, et al. FOXO₃^- induced oncogenic lncRNA CASC₉ enhances gefitinib resistance of non-small-cell lung cancer through feedback loop[J]. Life Sci, 2021, 287: 120012.
[10] 梁峰, 张玮, 王胜杰, 等. 干扰CASC9表达对结直肠癌细胞增殖、凋亡的影响及其与miR-195-5p/CCND1轴的关系[J]. 山东医药, 2021, 61(26): 1-5.
[11] ZHANG Y X, CHANG J Z, JIANG W W, et al. Long non-coding RNA CASC₉/microRNA-590-3p axis participates inlutein-mediated suppression of breast cancer cell proliferation [J]. Oncol Lett, 2021, 22(1): 544.
[12] LIU J, MAYEKAR M K, WU W, et al. Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G[J]. Cancer Lett, 2020, 493: 217-227.
[13] SHAO G L, WANG M C, FAN X L, et al. lncRNA CASC₉ positively regulates CHK₁ to promote breast cancer cell proliferation and survival through sponging the miR-195/497 cluster[J]. Int J Oncol, 2019, 54(5): 1665-1675.
[14] GAO G D, LIU X Y, LIN Y, et al. LncRNA CASC₉ promotes tumorigenesis by affecting EMT and predicts poor prognosis in esophageal squamous cell cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2): 422-429.
[15] YANG Y X, CHEN D, LIU H, et al. Increased expression of lncRNA CASC₉ promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma[J]. Cell Death Dis, 2019, 10 (2): 41.
[16] WU Y Y, HU L W, LIANG Y, et al. Up-regulation of lncRNA CASC₉ promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2[J]. Mol Cancer, 2017, 16(1): 150.
[17] ZHAN Y H, ZHANG L H, YU S B, et al. Long non- coding RNA CASC₉ promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer[J]. J Exp Clin Cancer Res, 2020, 39(1): 136.
[18] ZHAO W G, CHEN T B, ZHAO Y H. Upregulated lncRNA CASC₉ contributes to progression of non-small cell lung cancer through inhibition of miR-335-3p and activation S100A14 expression[J]. Onco Targets Ther, 2020, 13(11): 6027-6036.

长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义

Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李昕苇, 王全凯, 马顺鹏, 王苗, 乌瀚宝栎尔, 顾轶婷, 康同影, 许建宁. 甲基丙烯酸环氧丙酯诱导16HBE细胞恶性转化过程中LncRNA表达特征分析及ceRNA调控网络预测[J]. 癌变·畸变·突变, 2022, 34(1): 1-6.
[2]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[3]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[4]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[5]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[6]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[7]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[8]	李博, 李改瑞, 赵伟, 彭晓琳, 赵丹, 彭绩. 用于粪便DNA检测的样本保存液制作和效果评估[J]. 癌变·畸变·突变, 2021, 33(4): 312-316.
[9]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[10]	田薇, 方延, 吴晗恬, 吉布强, 夏昭林. 长链非编码RNA与mRNA在急性髓性白血病中的异常表达及其功能初探[J]. 癌变·畸变·突变, 2021, 33(2): 110-115.
[11]	马顺鹏, 王全凯, 王苗, 宋佳阳, 乌瀚宝栎尔, 谢广云, 许建宁. 甲基丙烯酸环氧丙酯诱导16HBE细胞恶性转化过程中细胞凋亡相关lncRNA的筛选及功能研究[J]. 癌变·畸变·突变, 2021, 33(1): 1-5,31.
[12]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[13]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[14]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[15]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.